A new era in HIV prevention dawned this week across Southern Africa. South Africa, Eswatini, and Zambia initiated public distribution of a revolutionary injection poised to dramatically alter the fight against the virus – a disease that disproportionately impacts the continent.
Lenacapavir, administered just twice a year, offers an astonishing level of protection. Clinical trials demonstrate a greater than 99.9 percent reduction in HIV transmission risk, effectively mimicking the preventative power of a vaccine. This breakthrough represents a monumental leap forward in safeguarding vulnerable populations.
The initial rollout in South Africa, a nation where one in five adults lives with HIV, is being carefully managed by a research unit at Wits University. This pioneering program aims to bring this life-altering preventative measure to those who need it most, marking the first real-world application of the injectable in low- and middle-income countries.
While the current cost of the drug remains substantial – $28,000 annually in the United States – a broader national rollout is planned for next year. Neighboring Zambia and Eswatini also received initial supplies of 1,000 doses each, timed to coincide with World AIDS Day observances.
A critical agreement with the pharmaceutical manufacturer, Gilead Sciences, will provide lenacapavir at no profit for up to two million individuals in high-burden countries over the next three years. However, advocates argue this quantity falls short of the actual need and that the initial price point remains inaccessible for many.
Eastern and Southern Africa bear the heaviest burden of the global HIV epidemic, accounting for over half of the 40.8 million people living with the virus worldwide. This makes the introduction of such a potent preventative tool particularly vital for the region’s public health.
Looking ahead, a significant reduction in cost is anticipated. Generic versions of lenacapavir are projected to become available by 2027, priced around $40 per year in over 100 countries. This accessibility is being facilitated through collaborative agreements between Unitaid, the Gates Foundation, and Indian pharmaceutical companies.
For over a decade, pre-exposure prophylaxis (PrEP) has been a cornerstone of HIV prevention. However, its reliance on daily pill adherence has presented challenges. Lenacapavir’s infrequent injection schedule offers a potentially transformative solution, promising to overcome barriers to consistent protection and significantly impact global infection rates.
